Get Unlimited Plan at 75% OFF!
IOL Chemicals & Pharmaceuticals
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
IOL Chemicals and Pharmaceuticals Ltd is a leading organic chemicals manufacturer and supplier in India. The company manufactures active pharmaceutical ingredient, organic chemicals and intermediates. The company was incorporated in the year 1986.
The company manufactures and supplies industrial chemicals and bulk drugs for use in various pharmaceutical applications. Their portfolio includes industrial chemicals, industrial organic chemicals and bulk drugs.
The company has two segments namely chemicals and pharmaceuticals. Under the chemical division, the company manufactures bulk chemicals, such as acetic acid and specialty chemicals, including ethyl acetate and acetic anhydride. Under pharmaceuticals division, the company manufactures active pharmaceutical ingredient, Ibuprofen.
The company has two manufacturing units namely API Unit and Chemical Unit located in Punjab. API Unit manufactures Ibuprofen with the installed Capacity of 10 MTPD. Chemical Unit manufactures organic chemicals such as Glacial Acetic Acid, Ethyl Acetate, Acetic Anhydride, Mono chloro acetic Acid, Acetyl Chloride and Iso butyl Benzene.
The company is having their presence in over 40 countries across the world, which includes Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt, and many others. They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy. DS Group, Cipla, Uflex Industries, ITC Ltd, ICI Paints, Asian Paints, Pidillte, Rallis India, Hindustan Polymide, Gujarat Super Phosphate and Avon Organics Ltd etc.
The capacity enhancement project and Multi Product PPIs Plant and other pharmaceutical intermediate products with a CAPEX of Rs 130 crore was completed in 2012. The Company undertook another project of multi product plant for manufacture active pharmaceutical ingredients and upgrading of R&D facilities involving a CAPEX of Rs 58.41 crore.
G Drugs and Pharmaceuticals Limited (GDPL) was merged with Company, through The Board for Industrial and Financial Reconstruction (BIFR), vide its order dated 15 March 2012, with appointed date of 1 April 2010. The said Merger was made effective on 20 April 2012 and consequently GDPL ceased to exit from that date.
During the current year 2016-17, the Company converted its existing multiple purpose plant into a dedicated ibuprofen manufacturing facility and resulting to its conversion, the ibuprofen manufacturing facility increased from 6200 TPA to 7200 TPA. During year 2017-18, Unit III to manufacture Fenofi brate, Clopidogrel and Lamotrigine Project was set up which costed Rs 16.48 crore. The company also setup Unit IV for manufacturing Metformin an anti-diabetic drug with a capacity of 3000 MT per annum with project cost of Rs 10.02 crore. It enhanced installed capacity of Ibuprofen from 7200 TPA to 10000 TPA by debottlenecking and re-engineering the plant in the month of August 2018.
During year 2019, the Company has enhanced installed capacity of Metformin from 3,000 TPA to 4,000 TPA with a capex of Rs 2.71 crore; it set up Unit V o manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 MT per annum with capex of Rs 19.26 crore; it further enhanced existing manufacturing facilities of Ibuprofen from 10,000 TPA to 12,000 TPA and Iso Butyl Benzene from 9,000 TPA to 12,000 TPA in May 2019 with capex of Rs 12.10 crore. During 2020, the Company set up 'Unit VI', with an installed capacity of 240 MT per annum, which costed Rs 33.83 Crore, to manufacture 'Pantoprazole' and has started its trial production. During 2021, the Company set up an another Unit-7 for manufacturing Metformin with an additional capacity of 7,200 MT per annum for project costing Rs 28 cr. It installed new manufacturing facilities 'Unit-8' to manufacture Ibuprofen Derivatives and other Pharma Products during FY 2020-21. It increased existing manufacturing facilities of Ethyl Acetate from 87,000 MT per annum to 100,000 MT per annum in Chemical segment during 2021-22.
During the year 2022-23, IOL- Foundation was incorporated as wholly owned subsidiary company. The Company set up multi product manufacturing facilities Unit 10' for manufacturing pharma APIs. It identified to manufacture Fenofibrate, Lamotrigine etc in this unit. Further, it also initiated the project for installation of new manufacturing facilities (Unit-9) for manufacturing Gabapentin and other Pharma products during the year, which is under implementation.
IOL Chemicals & Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of IOL Chemicals & Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how IOL Chemicals & Pharmaceuticals is valued compared to its competitors.
IOL Chemicals & Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to IOL Chemicals & Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of IOL Chemicals & Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively IOL Chemicals & Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of IOL Chemicals & Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of IOL Chemicals & Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of IOL Chemicals & Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of IOL Chemicals & Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of IOL Chemicals & Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of IOL Chemicals & Pharmaceuticals Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where IOL Chemicals & Pharmaceuticals shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect IOL Chemicals & Pharmaceuticals ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of IOL Chemicals & Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of IOL Chemicals & Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of IOL Chemicals & Pharmaceuticals .
The balance sheet presents a snapshot of IOL Chemicals & Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App